# AN2 Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:b92e141d-3c35-4f76-afa0-2d12534e9412 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/an2-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 20 | | Claims under review | 1 | | Evidence records | 3 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-19T14:44:56.273334+00:00 | | Last reviewed | 2026-10-19T14:44:56.273334+00:00 | ## Identity - Legal name: AN2 Therapeutics, Inc. - Display name: AN2 Therapeutics, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-20T04:41:46.61361+00:00 | | Completeness | 0.409 | | Record Quality | 0.818 | | Directors | 12 | | Committees | 1 | | Governance events | 4 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Gilbert Lynn Marks: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:6 - Melvin Spigelman: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2022-01-01. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:11 - Rob Readnour: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2019-01-01. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:14 - Eric Easom: President, Chief Executive Officer and Board Chair. Status: unknown. Independent: false. Since: NOT_PUBLISHED. Committees: Chief Executive Officer and Board Chair (member). claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:5 - Gilbert Lynn Marks, M.D.: Class I Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:7 - Joseph Zakrzewski: Class III Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:8 - Kabeer Aziz: Class I Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:9 - Margaret FitzPatrick: Class II Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:10 - Melvin Spigelman, M.D.: Class II Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:12 - Patricia Martin: Class II Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:13 - Rob Readnour, Ph.D.: Class I Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:15 - Stephanie Wong: Class III Director. Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:16 ## Committees - Chief Executive Officer and Board Chair (executive). Chair: NOT_PUBLISHED. Members: Eric Easom (member, unknown). committee_id=alpha:committee:an2-therapeutics-inc:chief-executive-officer-and-board-chair ## Executive leadership - Joshua Eizen: Chief Legal Officer and Chief Operating Officer [GC]. Status: current. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:18 - Eric Easom: President, Chief Executive Officer and Board Chair [CEO]. Status: unknown. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:17 - Lucy Day: Chief Financial Officer [CFO]. Status: unknown. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:19 - Sanjay Chanda, Ph.D.: Chief Development Officer. Status: unknown. claim_id=alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:20 ## Governance events - GC_CHANGED: Joshua Eizen executive of AN2 Therapeutics, Inc., effective 2026-04-22. Effective: 2026-04-22. Detected: 2026-10-19T14:44:56.273334+00:00. event_id=alpha:event:transition:yzcwh31c1zz0p - DIRECTOR_APPOINTED: Melvin Spigelman seat on AN2 Therapeutics, Inc., effective 2022-01-01. Effective: 2022-01-01. Detected: 2026-10-19T14:44:56.273334+00:00. event_id=alpha:event:transition:6d9yvkzmsglo - DIRECTOR_APPOINTED: Gilbert Lynn Marks seat on AN2 Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-19T14:44:56.273334+00:00. event_id=alpha:event:transition:73r30chpeqxk - DIRECTOR_APPOINTED: Rob Readnour seat on AN2 Therapeutics, Inc., effective 2019-01-01. Effective: 2019-01-01. Detected: 2026-10-19T14:44:56.273334+00:00. event_id=alpha:event:transition:o9ojx9frgl69 ## Scoped resources - `alpha://company/an2-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record - `alpha://company/an2-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=identity - `alpha://company/an2-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/an2-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=board - `alpha://company/an2-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=committees - `alpha://company/an2-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=leadership - `alpha://company/an2-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=ownership - `alpha://company/an2-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=financials - `alpha://company/an2-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/an2-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=compensation - `alpha://company/an2-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=governance - `alpha://company/an2-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/an2-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=audit - `alpha://company/an2-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=legal - `alpha://company/an2-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=risk - `alpha://company/an2-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=cyber - `alpha://company/an2-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/an2-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=agents - `alpha://company/an2-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/an2-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=events - `alpha://company/an2-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=relationships - `alpha://company/an2-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=assessments - `alpha://company/an2-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - Eric Easom: President, Chief Executive Officer and Board Chair. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Gilbert Lynn Marks: Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:6. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e10fed456a43b70a587b5109ca2cb87fcfaa687ce890bfeea732f57354252f4d. - Gilbert Lynn Marks, M.D.: Class I Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:7. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Joseph Zakrzewski: Class III Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:8. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Kabeer Aziz: Class I Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:9. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Margaret FitzPatrick: Class II Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:10. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Melvin Spigelman: Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:11. Valid from: 2022-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e10fed456a43b70a587b5109ca2cb87fcfaa687ce890bfeea732f57354252f4d. - Melvin Spigelman, M.D.: Class II Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:12. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Patricia Martin: Class II Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Rob Readnour: Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:14. Valid from: 2019-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e10fed456a43b70a587b5109ca2cb87fcfaa687ce890bfeea732f57354252f4d. - Rob Readnour, Ph.D.: Class I Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:15. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Stephanie Wong: Class III Director. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Eric Easom: President, Chief Executive Officer and Board Chair. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Joshua Eizen: Chief Legal Officer and Chief Operating Officer. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:18. Valid from: 2026-04-22. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e10fed456a43b70a587b5109ca2cb87fcfaa687ce890bfeea732f57354252f4d. - Lucy Day: Chief Financial Officer. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. - Sanjay Chanda, Ph.D.: Chief Development Officer. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:leadership_role:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - AN2 Therapeutics, Inc.. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f7d1b14f1d86bcde1810e291cf73ed9b75a707346e3c4fc17c4a24ae40feaabf. ## Entity Status - Public listing published. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f7d1b14f1d86bcde1810e291cf73ed9b75a707346e3c4fc17c4a24ae40feaabf. ## Published Fact - US. Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f7d1b14f1d86bcde1810e291cf73ed9b75a707346e3c4fc17c4a24ae40feaabf. ## Security Listing - ANTX (NASDAQ). Claim: alpha:claim:company:b92e141d-3c35-4f76-afa0-2d12534e9412:security_listing:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f7d1b14f1d86bcde1810e291cf73ed9b75a707346e3c4fc17c4a24ae40feaabf. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:f7d1b14f1d86bcde1810e291cf73ed9b75a707346e3c4fc17c4a24ae40feaabf: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/an2-therapeutics-inc). - alpha:projection-evidence:document:7925842f51119a208976f0410a394e16eca46ac39eb6e0ecf6d1d893df01c917: [SEC DEF 14A 0001193125-26-170314](https://www.sec.gov/Archives/edgar/data/1880438/000119312526170314/antx-20260422.htm). - alpha:projection-evidence:document:e10fed456a43b70a587b5109ca2cb87fcfaa687ce890bfeea732f57354252f4d: [DEF 14A antx-20260422.htm](https://www.sec.gov/Archives/edgar/data/1880438/000119312526170314/antx-20260422.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/an2-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/an2-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/an2-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/an2-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-20T04:41:46.36191+00:00; recorded 2026-10-20T04:41:46.36191+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.